Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 286

Sort by

Sort Order Select

Journal Articles

B-cell receptor signaling and genetic lesions in TP53 and CDKN2A/CDKN2B cooperate in Richter transformation

Supriya Chakraborty, Claudio Martines, Fabiola Porro, Ilaria Fortunati, Alice Bonato, Marija Dimishkovska, Silvano Piazza, Brijesh S. Yadav, Idanna Innocenti, Rosa Fazio, Tiziana Vaisitti, Silvia Deaglio, Alberto Zamò, Aleksandar J. Dimovski, Luca Laurenti, Dimitar G. Efremov

Blood (2021) 138 (12): 1053–1066.

https://doi.org/10.1182/blood.2020008276

Published: 2021

Includes: Supplemental data

Journal Articles

A common protein target for an uncommon subtype of AML

Martin Carroll

Blood (2020) 136 (4): 377–378.

https://doi.org/10.1182/blood.2020006487

Published: 2020

Journal Articles

CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia

Blood (2020) 136 (4): 387–400.

https://doi.org/10.1182/blood.2019003267

Published: 2020

Includes: Supplemental data

Journal Articles

Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by CDK6-specific PROTACs

Marco De Dominici, Patrizia Porazzi, Youcai Xiao, Allen Chao, Hsin-Yao Tang, Gaurav Kumar, Paolo Fortina, Orietta Spinelli, Alessandro Rambaldi, Luke F. Peterson, Svetlana Petruk, Camilla Barletta, Alexander Mazo, Gino Cingolani, Joseph M. Salvino, Bruno Calabretta

Blood (2020) 135 (18): 1560–1573.

https://doi.org/10.1182/blood.2019003604

Published: 2020

Includes: Supplemental data

Journal Articles

Mechanistic Basis and Efficacy of Targeting β-Catenin-TCF7L2-JMJD6-MYC Axis to Overcome Resistance to BET Inhibitors

Christopher Peter Mill, PhD BA, Warren Fiskus, BSc,PhD, Dyana T. Saenz, PhD, Bernardo H Lara, Vrajesh Karkhanis, PhD, Taghi Manshouri, PhD, Isean Bhalla, Nancy Shao, James V Maher, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

Blood (2019) 134 (Supplement_1): 538.

https://doi.org/10.1182/blood-2019-125142

Published: 2019

Journal Articles

Composite Copy Number Variation in CDK4 , CDKN2A and RB1 Predisposes Mantle Cell Lymphoma to Expansion of PD1+ Tumor Cells and Resistance to CDK4/6 Inhibitor Therapy as Revealed by Integrative Longitudinal scRNA-seq

Maurizio Di Liberto, PhD, Yang Hu, PhD, Xiangao Huang, PhD, Christina Y. Lee, MD, Kevin Wang, B.S., Nancy L. Bartlett, MD, LeAnn Ridling, Kristie A. Blum, MD, Kami J. Maddocks, MD, Steven I Park, MD, Jia Ruan, MD PhD, Kenneth Eng, B.S., Lorenzo Galluzzi, PhD, John P. Leonard, MD, Peter Martin, FRCPC, MD MS, Olivier Elemento, PhD, Selina Chen-Kiang, PhD

Blood (2019) 134 (Supplement_1): 1492.

https://doi.org/10.1182/blood-2019-130944

Published: 2019

Journal Articles

Comprehensive Genomic Profiling of 104 Rare Histiocytic and Dendritic Cell Neoplasms Reveals Shared and Distinct Targetable Genomic Alterations

Lucas R. Massoth, MD, Yin P. Hung, MD, PhD, Judith A. Ferry, MD, Robert P. Hasserjian, MD, Abner Louissaint, Jr., MD PhD, Meagan Montesion, PhD, Ethan S. Sokol, PhD, Dean C. Pavlick, Nikunj Shah, Natalie Danziger, Jonathan Keith Killian, MD,PhD, Eric A. Severson, MD, PhD, MMSc, Daniel Duncan, MD, Julia A. Elvin, MD, PhD, Vincent A. Miller, MD, Jeffrey S. Ross, MD, Jo-Anne Vergilio, MD, Lawrence R. Zukerberg, MD, Erik A. Williams, MD

Blood (2019) 134 (Supplement_1): 2541.

https://doi.org/10.1182/blood-2019-123729

Published: 2019

Journal Articles

Disrupting GRINL1A Association with Cereblon Accelerates IKZF1/3 Degradation and IMiD Killing of Mantle Cell Lymphoma Cells By CDK4/6 Inhibition

Nicole Zhao, Maurizio Di Liberto, PhD, Olivier Elemento, PhD, Selina Chen-Kiang, PhD, Xiangao Huang, PhD

Blood (2019) 134 (Supplement_1): 299.

https://doi.org/10.1182/blood-2019-128927

Published: 2019

Journal Articles

Genome-Wide CRISPR Library Screening Identifies CDK6 As Genetic Vulnerability in Adult T-Cell Leukemia/Lymphoma

Takashi Ishio, Joji Shimono, Sarvesh Kumar, Yuquan Lin, Emmanuel Bachy, Michael N. Petrus, Yandan Yang, Michiyuki Maeda, Hideki Goto, Satoshi Hashino, Takanori Teshima, MD, Thomas A. Waldmann, MD, Louis Staudt, MD, Masao Nakagawa

Blood (2019) 134 (Supplement_1): 3781.

https://doi.org/10.1182/blood-2019-124670

Published: 2019

Journal Articles

T-Cell Clonal Expansion and Activation Associated with Durable Clinical Response to Dual BTK and CDK4/6 Inhibitor Therapy in Mantle Cell Lymphoma

Christina Y. Lee, MD, Maurizio Di Liberto, PhD, Yang Hu, PhD, Xiangao Huang, PhD, Nancy L Bartlett, MD, Kami J. Maddocks, MD, John P. Leonard, MD, Nils-Petter Rudqvist, PhD, Lorenzo Galluzzi, PhD, Peter Martin, FRCPC, MD MS, Olivier Elemento, PhD, Selina Chen-Kiang, PhD

Blood (2019) 134 (Supplement_1): 3973.

https://doi.org/10.1182/blood-2019-122322

Published: 2019

Journal Articles

ETH-155008, a Novel Selective Dual Inhibitor of FLT3 and CDK4/6 in Preclinical Treatment of Acute Myeloid Leukemia

Changnian Liu, PhD MD, Bin Liu, MSc, Chunping Xu, PhD, Pan Zhang, Bin Li, Bin Ji, Bin Zhang, Qingjun Liu, PhD, James Zhang, MSc, Chengzhi Yu, PhD

Blood (2019) 134 (Supplement_1): 5141.

https://doi.org/10.1182/blood-2019-123589

Published: 2019

Journal Articles

Gene Expression Profiling Using Nanostring™ Reveals Differences According to Location, Histology and MIPI Score in Mantle Cell Lymphoma

Diana Lucia Martínez Baquero, MD, Ken H. Young, Roberto N. Miranda, MD, L. Jeffrey Medeiros, MD, Chi Young Ok, MD

Blood (2019) 134 (Supplement_1): 5218.

https://doi.org/10.1182/blood-2019-132056

Published: 2019

Journal Articles

HO-1 Promotes Resistance to EZH2 Inhibitor through the Prb-E2F Pathway: Corelated with the Conversion of Myelodysplastic Syndrome to Acute Myeloid Leukemia

Zhengchang He, Jishi Wang, PhD

Blood (2019) 134 (Supplement_1): 5401.

https://doi.org/10.1182/blood-2019-131573

Published: 2019

Journal Articles

CDK6 Antagonizes TP53-Induced Responses during Tumorigenesis

Veronika Sexl, MD PhD, Karoline Kollmann, PhD, Florian Bellutti

Blood (2019) 134 (Supplement_1): SCI-15.

https://doi.org/10.1182/blood-2019-121101

Published: 2019

Journal Articles

The CDK6 Inhibitor Palbociclib in Combination with Ruxolitinib Remarkably Improves Myelofibrosis in Murine Models

Golam Mohi, PhD, Avik Dutta, PhD, Dipmoy Nath, PhD, Yue Yang, PhD

Blood (2019) 134 (Supplement_1): 4200.

https://doi.org/10.1182/blood-2019-132038

Published: 2019

Journal Articles

A CRISPR/Cas9-Generated Murine Model Reveals Cooperation between BCR Signaling and CDKN2A/2B and TP53 Disruption in Richter Syndrome

Supriya Chakraborty, PhD, Ilaria Fortunati, BS, Claudio Martines, MS, Brijesh Yadav, PhD, Marija Dimishkovska, PhD, Idanna Innocenti, MD PhD, Rosa Fazio, BS, Giovanni D'Arena, MD, Aleksandar Dimovski, MD PhD, Luca Laurenti, MD, Dimitar G Efremov, MD PhD

Blood (2019) 134 (Supplement_1): 4278.

https://doi.org/10.1182/blood-2019-128425

Published: 2019

Journal Articles

Notch1 mutation in B Chronic Lymphocytic Lymphocytes Induces Proliferation through Cell Cycle G1/S Phase-Specific Cyclin Overexpression

Ana M Hurtado López, Tzu Hua Chen-Liang, María Zurdo, Anna Puiggros, PhD, Andrea Gómez-Llonín, B.Sc., María-Dolores García-Malo, MD, Francisco José Ortuño, Vicente Vicente Garcia, MD PhD, Blanca Espinet, PhD, Andres Jerez

Blood (2019) 134 (Supplement_1): 851.

https://doi.org/10.1182/blood-2019-127960

Published: 2019

Journal Articles

A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma

Peter Martin, Nancy L. Bartlett, Kristie A. Blum, Steven Park, Kami Maddocks, Jia Ruan, LeAnn Ridling, Christopher Dittus, Zhengming Chen, Xiangao Huang, Giorgio Inghirami, Maurizio DiLiberto, Selina Chen-Kiang, John P. Leonard

Blood (2019) 133 (11): 1201–1204.

https://doi.org/10.1182/blood-2018-11-886457

Published: 2019

Journal Articles

Phase I Study of Palbociclib Alone and in Combination in Patients with Relapsed and Refractory (R/R) Leukemias

Tapan M. Kadia, MD, Marina Y. Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Christopher B. Benton, MD, William G. Wierda, MD PhD, Prithviraj Bose, MD, Musa E. Yilmaz, MD, Elias J. Jabbour, MD, Steven M. Kornblau, MD, Kapil N. Bhalla, MD, Naveen Pemmaraju, MD, Nitin Jain, MD, Rashmi Malla, RN, BSN, Gautam Borthakur, MD, Jorge E. Cortes, MD, Farhad Ravandi, MD, Hagop M. Kantarjian, MD

Blood (2018) 132 (Supplement 1): 4057.

https://doi.org/10.1182/blood-2018-99-117334

Published: 2018

Journal Articles

Novel Thyrointegrin αvβ3 Antagonist for the Treatment of Acute Myeloid Leukemia

Shaker A Mousa, PhD BPharm, MBA, MSc, Thangirala Institute Sudha, PhD, Kavitha Godugu, PhD, Mehdi Rajabi, PhD, Nazeer Tipu, MD, Paul J Davis, MD

Blood (2018) 132 (Supplement 1): 4068.

https://doi.org/10.1182/blood-2018-99-119455

Published: 2018

NARROW

B-cell receptor signaling and genetic lesions in TP53 and CDKN2A/CDKN2B cooperate in Richter transformation

A common protein target for an uncommon subtype of AML

CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia

Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by CDK6-specific PROTACs

Mechanistic Basis and Efficacy of Targeting β-Catenin-TCF7L2-JMJD6-MYC Axis to Overcome Resistance to BET Inhibitors

Composite Copy Number Variation in CDK4 , CDKN2A and RB1 Predisposes Mantle Cell Lymphoma to Expansion of PD1+ Tumor Cells and Resistance to CDK4/6 Inhibitor Therapy as Revealed by Integrative Longitudinal scRNA-seq

Comprehensive Genomic Profiling of 104 Rare Histiocytic and Dendritic Cell Neoplasms Reveals Shared and Distinct Targetable Genomic Alterations

Disrupting GRINL1A Association with Cereblon Accelerates IKZF1/3 Degradation and IMiD Killing of Mantle Cell Lymphoma Cells By CDK4/6 Inhibition

Genome-Wide CRISPR Library Screening Identifies CDK6 As Genetic Vulnerability in Adult T-Cell Leukemia/Lymphoma

T-Cell Clonal Expansion and Activation Associated with Durable Clinical Response to Dual BTK and CDK4/6 Inhibitor Therapy in Mantle Cell Lymphoma

ETH-155008, a Novel Selective Dual Inhibitor of FLT3 and CDK4/6 in Preclinical Treatment of Acute Myeloid Leukemia

Gene Expression Profiling Using Nanostring™ Reveals Differences According to Location, Histology and MIPI Score in Mantle Cell Lymphoma

HO-1 Promotes Resistance to EZH2 Inhibitor through the Prb-E2F Pathway: Corelated with the Conversion of Myelodysplastic Syndrome to Acute Myeloid Leukemia

CDK6 Antagonizes TP53-Induced Responses during Tumorigenesis

The CDK6 Inhibitor Palbociclib in Combination with Ruxolitinib Remarkably Improves Myelofibrosis in Murine Models

A CRISPR/Cas9-Generated Murine Model Reveals Cooperation between BCR Signaling and CDKN2A/2B and TP53 Disruption in Richter Syndrome

Notch1 mutation in B Chronic Lymphocytic Lymphocytes Induces Proliferation through Cell Cycle G1/S Phase-Specific Cyclin Overexpression

A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma

Phase I Study of Palbociclib Alone and in Combination in Patients with Relapsed and Refractory (R/R) Leukemias

Novel Thyrointegrin αvβ3 Antagonist for the Treatment of Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only